Semaglutide belongs to a class called GLP-1 receptor agonists, and the mechanism is worth understanding before starting. GLP-1 is a hormone your gut releases after eating. It tells the pancreas to release insulin, slows how quickly the stomach empties, and signals the brain that you have had enough. Semaglutide mimics that hormone with a structure that resists breakdown, which is why it is dosed once weekly rather than after every meal. It is not a stimulant and it does not accelerate metabolism — it works by extending a satiety signal your body already produces. Every protocol is physician-reviewed, and dosing is titrated gradually.
Jacksonville Beach:
904.372.4401
Riverside:
904.337.0746
Benefits
Supports appetite regulation and blood sugar signaling through the body’s own GLP-1 pathway.
- Once-weekly dosing rather than daily administration
- Works through an existing hormonal pathway rather than stimulant activity
- Associated with slowed gastric emptying and extended satiety signaling
- Associated with glucose-dependent insulin release
- Physician-reviewed protocol with gradual dose titration
Safety Information
Nausea, vomiting, diarrhea, and constipation are the most commonly reported effects and are typically most pronounced early in a protocol and during dose increases. Semaglutide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Discuss any history of pancreatitis, gallbladder disease, gastroparesis, or diabetic retinopathy with your provider. Not for use during pregnancy or breastfeeding. This protocol requires clinical evaluation and ongoing provider monitoring.
Regimen
Once-weekly injection on the same day each week. Dosing begins low and is titrated upward by your provider over the course of the protocol. Timing relative to meals is not required.
How to Take
Subcutaneous injection near the lower abdomen, outer thigh, or back of the upper arm. Use sterile technique. Rotate injection sites weekly.
How It Works
Semaglutide is a synthetic analog of glucagon-like peptide-1, an incretin hormone released by intestinal cells in response to food. Structural modifications make it resistant to the enzyme that normally degrades GLP-1 within minutes, extending its activity to roughly a week. At the receptor level, it is associated with three effects: glucose-dependent insulin secretion from the pancreas, meaning insulin release scales with blood sugar rather than occurring indiscriminately; suppression of glucagon, the opposing hormone; and slowed gastric emptying, which extends the physical sensation of fullness. It also acts on appetite-regulating regions of the hypothalamus. The result is amplification of a satiety signal the body generates on its own.
Semaglutide has one of the largest clinical evidence bases of any peptide in use. It has been studied in multiple large randomized controlled trials involving tens of thousands of participants, and FDA-approved formulations exist for type 2 diabetes and for chronic weight management. Those trials are the source of everything described above — the mechanism, the gradual titration schedule, the gastrointestinal side effect profile, and the thyroid and pancreatitis contraindications. The mechanism is well understood: GLP-1 receptor activation produces glucose-dependent insulin release, glucagon suppression, slowed gastric emptying, and central appetite signaling. Compounded semaglutide is a different product from the FDA-approved formulations. It is prepared by a licensed compounding pharmacy for an individual patient under prescription and is not FDA-approved. It requires a clinical evaluation, documented medical need, and ongoing provider monitoring.
FAQs
What is semaglutide?
A GLP-1 receptor agonist — a synthetic version of a hormone your gut releases after eating. It signals the pancreas to release insulin when blood sugar is elevated, slows how quickly the stomach empties, and acts on appetite centers in the brain.
How does semaglutide affect appetite?
It extends a satiety signal your body already produces. GLP-1 slows gastric emptying so fullness lasts longer, and acts on the hypothalamus to reduce appetite. It is not a stimulant and does not raise metabolism.
How is semaglutide dosed?
Once weekly by subcutaneous injection, on the same day each week. Dosing starts low and is increased gradually by your provider over the course of the protocol to minimize side effects.
What are the side effects of semaglutide?
Nausea, vomiting, diarrhea, and constipation are the most common, particularly early and during dose increases. Semaglutide is not appropriate for anyone with a personal or family history of medullary thyroid carcinoma or MEN2, and requires provider review for any history of pancreatitis or gallbladder disease.
Is compounded semaglutide the same as the FDA-approved medication?
No. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under prescription. It is not an FDA-approved product. Your provider will discuss which option is appropriate for your situation.
How to Use Your Peptides
Before you get started with your peptide protocol, we recommend reviewing our Injection Guide to ensure safe and effective use. This quick-reference document walks you through proper subcutaneous injection technique, storage tips, and other best practices.
Each protocol below includes recommended timing, injection instructions, safety notes, and how the peptides work in your body. As always, please follow your provider’s guidance, and please reach out with any questions!
Book a Consultation
More Like Semaglutide
Not all patients qualify for all treatments – book a free consultation to find out what program is right for you.